

Press Release

AdvanceCOR GmbH Has Received Funding from the German Federal Ministry of Education (BMBF) and the Bavarian Research Foundation

Munich/Martinsried, May 2016

The German Federal Ministry of Research and Education (BMBF) has awarded a grant within the “individualized medicine” initiative (which is managed by DLR, Bonn) to the biotech company AdvanceCOR GmbH. The research funding covers an R&D program of about EUR 900.000.- to develop GPVI-Fc (Revacept) in further medical indications. Moreover, research work will be carried out at the team of Prof. Meinrad Gawaz, Medical Clinic of the University of Tübingen. A second phase II clinical study in patients with coronary artery disease will be carried out at the team of Prof. Adnan Kastrati, German Heart Center, Munich and the team of Prof. Steffen Massberg, Großhadern Clinic of the Ludwig-Maximilian University, and at further large clinical entities which are all organized within the Munich Heart Alliance of the German Center for Cardiovascular Diseases (DZHK; <http://dzhk.de/1/>). The trial will include patients with coronary artery disease who present with an indication for heart catheterisation and coronary stenting. The resulting myocardial damage will be evaluated by measuring troponin I levels. Moreover, drug safety will be investigated in these patients with a special focus on bleeding complications.

Already as of April 2015, the Bavarian Research Foundation has allowed a grant on further research on glycoprotein VI fusion proteins and applications, including additional biochemical functions to advanceCOR in a consortium with Prof. Wolfgang Siess at IPEK (Institute for Prophylaxis and Therapy of Cardiovascular Diseases, directed by Prof. Christian Weber) – which is also a member of the Munich Heart Alliance of the German Center for Cardiovascular Diseases (DZHK).

About GPVI-Fc (Revacept):

Dimeric GPVI-Fc (Revacept) is a lesion-specific inhibitor of arterial thrombosis for the treatment of patients with acute thromboembolic diseases such as stroke acute coronary syndromes and. Revacept has the unique feature to potently inhibit the initial steps of platelet activation without affecting general hemostasis. A current phase II study in patients with symptomatic carotid artery stenosis, TIA or stroke investigates micro-embolic signals in brain arteries (determined by ultrasound), clinical results, MRI tomography, and blood parameters (e. g. platelet aggregation). So far, no relevant adverse effects have been observed. Due to the blinded study design, the analysis of efficacy will be done at the end of the trial.

About AdvanceCOR GmbH

AdvanceCOR GmbH is a biotechnology company located in Martinsried near Munich, Germany. AdvanceCOR owns several clinical and preclinical projects generated from its own scientific program or from the university groups of the company’s founders.

For more information please contact

AdvanceCOR GmbH
Barbara Amberg
Fraunhoferstr. 9a
D-82152 Martinsried
Tel. ++49 (0)89 2000 204 10
Email: info@advancecor.com